News | May 14, 2026
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
This marks the second consecutive year that Juneja has made a personal contribution towards supporting the armed forces
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
